These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 25873248)
41. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Saxe PA; Arnold LM; Palmer RH; Gendreau RM; Chen W Curr Med Res Opin; 2012 May; 28(5):815-21. PubMed ID: 22429066 [TBL] [Abstract][Full Text] [Related]
42. Non-specific analgesia during a clinical trial in fibromyalgia. Dualé C; Macian N; Giron F; Pickering G Eur J Clin Invest; 2020 Nov; 50(11):e13337. PubMed ID: 32585738 [TBL] [Abstract][Full Text] [Related]
43. A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine. Engel ER; Kudrow D; Rapoport AM Neurol Sci; 2014 Mar; 35(3):429-35. PubMed ID: 24030685 [TBL] [Abstract][Full Text] [Related]
44. The dubious effect of milnacipran for the treatment of burning mouth syndrome. Sugimoto K Clin Neuropharmacol; 2011; 34(4):170-3. PubMed ID: 21738026 [TBL] [Abstract][Full Text] [Related]
45. Pharmacotherapy of fibromyalgia. Traynor LM; Thiessen CN; Traynor AP Am J Health Syst Pharm; 2011 Jul; 68(14):1307-19. PubMed ID: 21719591 [TBL] [Abstract][Full Text] [Related]
47. Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia. Petzke F; Jensen KB; Kosek E; Choy E; Carville S; Fransson P; Williams SCR; Marcus H; Mainguy Y; Ingvar M; Gracely RH Scand J Pain; 2013 Apr; 4(2):65-74. PubMed ID: 29913906 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of the efficacy of memantine in the treatment of fibromyalgia: study protocol for a doubled-blind randomized controlled trial with six-month follow-up. Olivan-Blázquez B; Puebla M; Masluk B; Pérez-Yus MC; Arcega R; Andrés E; López-del-Hoyo Y; Magallon R; Roca M; Garcia-Campayo J Trials; 2013 Jan; 14():3. PubMed ID: 23286311 [TBL] [Abstract][Full Text] [Related]
49. Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. Lee YH; Song GG Rheumatol Int; 2016 May; 36(5):663-72. PubMed ID: 27000046 [TBL] [Abstract][Full Text] [Related]
50. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Mease PJ Am J Med; 2009 Dec; 122(12 Suppl):S44-55. PubMed ID: 19962496 [TBL] [Abstract][Full Text] [Related]
51. [Between depression and fibroniyalgia: the fate of the antidepressant]. Drobizhev MY; Fedotova AV; Kikta SV; Antokhin EY Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):114-120. PubMed ID: 27386594 [TBL] [Abstract][Full Text] [Related]
52. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia. Palmer RH; Periclou A; Banerjee P Ther Adv Musculoskelet Dis; 2010 Aug; 2(4):201-20. PubMed ID: 22870448 [TBL] [Abstract][Full Text] [Related]
53. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Steen A; Den Boer JA Int Clin Psychopharmacol; 1997 Sep; 12(5):269-81. PubMed ID: 9466161 [TBL] [Abstract][Full Text] [Related]
54. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S; Pletan Y; Solles A; Tournoux A Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125 [TBL] [Abstract][Full Text] [Related]
55. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Arnold LM; Palmer RH; Ma Y Clin J Pain; 2013 Dec; 29(12):1021-8. PubMed ID: 23446068 [TBL] [Abstract][Full Text] [Related]
56. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Papakostas GI; Fava M Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224 [TBL] [Abstract][Full Text] [Related]
58. The evaluation of analgesic effects of milnacipran and sertraline in tail-flick test. Kesim M; Yanik MN; Kadioglu M; Pepeoglu D; Erkoseoglu I; Kalyoncu NI; Yaris E Bratisl Lek Listy; 2014; 115(1):3-6. PubMed ID: 24471894 [TBL] [Abstract][Full Text] [Related]
59. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report. Kito S; Nakajima T; Koga Y Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932 [No Abstract] [Full Text] [Related]
60. Pharmacology and pharmacokinetics of milnacipran. Puozzo C; Panconi E; Deprez D Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S25-35. PubMed ID: 12369608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]